Literature DB >> 23732222

Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children.

Sandra Asner1, Derek Stephens, Paul Pedulla, Susan E Richardson, Joan Robinson, Upton Allen.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) is associated with significant morbidity and mortality in immunocompromised children. Data on the risk factors for acquisition and outcomes from RSV infections in this population are limited.
METHODS: This cohort study (2006 to 2011) included RSV-positive immunocompromised pediatric inpatients. Nasopharyngeal swabs were tested for RSV by direct immunofluorescence. Purposeful multiple regression was used to assess risk factors associated with community-acquired RSV (CA-RSV) infections and their outcomes compared with nosocomial (N-RSV) infections. Means and medians were compared using Student's t test and a nonparametric test, respectively. Proportions were compared using χ(2) or Fisher's exact test, as appropriate.
RESULTS: There were 117 RSV-positive patients of whom 42 (35.9%) presented with (N-RSV) infection. Overall, more than a third presented with lower respiratory tract infections, which resulted in a 28% admission rate to the intensive care unit and a mortality rate of 5%; the latter solely among patients with community-acquired infection. Subjects with CA-RSV presented with more advanced clinical evidence of lower tract disease with respiratory distress (eg, intercostal recession; odds ratio 2.5; 95% confidence interval: 1.1-5.6; P = 0.03) compared with those with N-RSV. Subjects with CA-RSV infections were less likely to have a prolonged hospital admission (odds ratio 0.7; 95% confidence interval: 0.5-0.8; P < 0.0001) relative to those with N-RSV infections.
CONCLUSIONS: RSV-related infections in immunocompromised children may result in poor outcomes, including mortality. Differences in mortality rates among those with CA-RSV compared with N-RSV warrant further study, with enhanced opportunities for prevention and early detection of infection.

Entities:  

Mesh:

Year:  2013        PMID: 23732222     DOI: 10.1097/INF.0b013e31829dff4d

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

1.  Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus.

Authors:  Daniel M Weinberger; Joshua L Warren; Claudia A Steiner; Vivek Charu; Cécile Viboud; Virginia E Pitzer
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Depletion of TAX1BP1 Amplifies Innate Immune Responses during Respiratory Syncytial Virus Infection.

Authors:  Delphyne Descamps; Andressa Peres de Oliveira; Lorène Gonnin; Sarah Madrières; Jenna Fix; Carole Drajac; Quentin Marquant; Edwige Bouguyon; Vincent Pietralunga; Hidekatsu Iha; Armando Morais Ventura; Frédéric Tangy; Pierre-Olivier Vidalain; Jean-François Eléouët; Marie Galloux
Journal:  J Virol       Date:  2021-08-25       Impact factor: 5.103

3.  Respiratory Syncytial Virus Infection in High-risk Infants - an Update on Palivizumab Prophylaxis.

Authors:  Bernhard Resch
Journal:  Open Microbiol J       Date:  2014-07-11

4.  Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children.

Authors:  Helen Y Chu; Jennifer Chin; Jessica Pollard; Danielle M Zerr; Janet A Englund
Journal:  Influenza Other Respir Viruses       Date:  2016-03-23       Impact factor: 4.380

Review 5.  Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases.

Authors:  Paolo Manzoni; Josep Figueras-Aloy; Eric A F Simões; Paul A Checchia; Brigitte Fauroux; Louis Bont; Bosco Paes; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-06-26

6.  Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study.

Authors:  Olga Chatzis; Stephanie Darbre; Jérôme Pasquier; Pascal Meylan; Oriol Manuel; John David Aubert; Maja Beck-Popovic; Stavroula Masouridi-Levrat; Marc Ansari; Laurent Kaiser; Klara M Posfay-Barbe; Sandra A Asner
Journal:  BMC Infect Dis       Date:  2018-03-06       Impact factor: 3.090

7.  Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.

Authors:  Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; Laura L Ferlic-Stark; Kirtida D Patel; Felipe-Andres Piedra; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 8.  Interactions between the Nucleoprotein and the Phosphoprotein of Pneumoviruses: Structural Insight for Rational Design of Antivirals.

Authors:  Hortense Decool; Lorène Gonnin; Irina Gutsche; Christina Sizun; Jean-François Eléouët; Marie Galloux
Journal:  Viruses       Date:  2021-12-06       Impact factor: 5.048

Review 9.  Respiratory syncytial virus infections in infants affected by primary immunodeficiency.

Authors:  Marcello Lanari; Silvia Vandini; Maria Grazia Capretti; Tiziana Lazzarotto; Giacomo Faldella
Journal:  J Immunol Res       Date:  2014-06-25       Impact factor: 4.818

10.  Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus.

Authors:  M Boukhvalova; J C G Blanco; A R Falsey; J Mond
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.